Hong Kong-listed biotech firm uses AI to produce nano-rockets to deliver life-saving drugs

Shares of METiS TechBio surged 173 per cent on their Hong Kong debut on Wednesday as the AI-driven drug design start-up’s initial public offering drew strong demand from investors amid buoyant sentiment for AI-related stocks in the city. Its stocks traded at HK$28.68 at the open, climbing as high as HK$29.6 in the morning trading session before retreating to HK$23.8 at the close, up 126.67 per cent from the offering price. Co-founder and CEO of METiS TechBio, Lai Tsai-Ta, who obtained a PhD from...